Autoimmune and Inflammatory Disease · Gut and Inflammatory Bowel Disease

Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease

Godet PG, May GR, Sutherland LR

Published November 1995 Gut, 37(5), 668-673
DOI 10.1136/gut.37.5.668 PMID 8549943 PMC PMC1382872

Abstract

Numerous epidemiological studies have been performed to determine factors that might contribute to the development of inflammatory bowel disease. Although the role of oral contraceptive agents in Crohn's disease (CD) and ulcerative colitis (UC) have been assessed, most studies were of small sample size and characterised by low statistical precision. A meta-analysis was performed to increase the statistical power and to investigate the association between the use of oral contraceptives and the development of CD and UC. The study was based on a search of a Medline database from 1975 to October 1993 and a review of reference lists from published articles, reviews, symposia proceedings, and abstracts from major gastrointestinal meetings. All studies specifically designed to evaluate this association were selected. The combined results of nine studies--two cohort studies (30,379 unexposed and 30,673 exposed patients) and seven case-control studies (482 CD, 237 UC, and 3198 controls)--which satisfied our selection criteria were evaluated. The pooled relative risk (adjusted for smoking) associated with oral contraceptive use was 1.44 (1.12, 1.86) for CD and 1.29 (0.94, 1.77) for UC. These results suggest modest associations between the use of oral contraceptives and the development of CD and UC. As these associations are weak, non-causal explanations for the findings cannot be eliminated.

Topics

Related research

Autoimmune and Inflammatory Disease › Gut and Inflammatory Bowel Disease › Inflammatory Bowel Disease
PMID 8549943 8549943 DOI 10.1136/gut.37.5.668 10.1136/gut.37.5.668 Godet et al. 1995, Godet 1995

Cite this article

Godet, P., May, G. R., & Sutherland LR (1995). Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut, 37(5), 668-673. https://doi.org/10.1136/gut.37.5.668